What Is FGF12? Definition and What Research Reports

Definition

FGF12 (fibroblast growth factor 12), also known as fibroblast growth factor homologous factor 1 (FHF1), is a human gene and the protein it encodes. A 2024 review of FGF12 biology described the protein as a member of the fibroblast growth factor homologous factor subfamily — a group within the broader FGF superfamily whose members lack a conventional secretion signal, remain inside the cell, and are therefore not considered classical FGF-receptor ligands despite their structural similarity to secreted FGFs (PMID 38042708). In plain terms, FGF12 is an intracellular regulatory protein rather than a hormone-like growth factor that circulates between cells, and most of the literature about it is genetics and cell-biology research rather than pharmacology.

What Class of Molecule It Is, and Where It Comes From

FGF12 is a protein product of an endogenous human gene; it is not a synthetic analogue, not a fragment designed in a laboratory, and not a compound with an approved therapeutic version. The 2024 review characterised the FHF subfamily (FGF11–FGF14) as intracellular proteins that interact with partners such as voltage-gated sodium channels and intracellular signalling components, distinguishing them functionally from paracrine and endocrine FGFs (PMID 38042708). Because the protein is produced within cells that express the gene, published studies typically read it out by measuring gene or protein expression in tissue, by deleting or overexpressing it in animal models, or by sequencing patients with unexplained disease phenotypes.

That origin matters for how the term should be interpreted. Secreted FGFs such as FGF1, FGF2 or FGF21 have been studied as administered proteins in various models; the FHF branch that contains FGF12 has largely been studied as an intracellular participant in channel regulation and signalling, according to the same review (PMID 38042708).

How the Term Is Used in Peptide and Protein Research

In the research literature, "FGF12" usually appears in one of four ways:

• As a gene name in human genetics — for example, in reports of de novo variants identified in patients with severe early-onset epilepsy.
• As an expression marker — describing which tissues or cell types show elevated or reduced FGF12 levels in a disease state.
• As a manipulated target in animal or cell models — cell-type-specific knockout, knockdown or overexpression experiments used to test whether the protein is necessary or sufficient for a phenotype.
• As a mechanistic node — described in terms of the intracellular partners it binds or stabilises.

What the term is generally not used for is an administered compound. Across the verified literature summarised here, FGF12 appears as an endogenous protein studied through genetics and cell biology, not as a peptide given to animals or people at defined doses. There is accordingly no dosing, schedule or administration literature to summarise, and this page makes no statements about any.

What the Published Literature Reports

Neurological genetics

A 2016 report in Neurology: Genetics described FHF1 (FGF12) epileptic encephalopathy, linking a variant in the gene to an early infantile epileptic encephalopathy phenotype (PMID 27830185). This is the context in which clinicians most often encounter the gene name, and it is consistent with the intracellular sodium-channel-associated role that the 2024 review attributed to the FHF subfamily (PMID 38042708).

Skin and keratinocyte biology

A 2024 study in Advanced Science reported that FGF12 positively regulated keratinocyte proliferation by stabilising MDM2 and inhibiting p53 activity in the setting of psoriasis (PMID 39234815). In that work, researchers framed FGF12 as an upstream regulator of a proliferation-control axis inside skin cells rather than as a secreted factor acting on a receptor from outside.

Liver fibrosis in mice

A study published in Hepatology reported that macrophage-specific FGF12 promoted liver fibrosis progression in mice (PMID 35753047). The design was cell-type-specific — the protein's contribution was attributed to macrophages rather than to hepatocytes — which is why the study is usually cited as evidence that FGF12 expression in a particular immune compartment can influence a fibrotic disease course in an animal model.

Vascular smooth muscle and aortic disease

A 2026 report in Experimental & Molecular Medicine described FGF12 inducing aberrant mechanosignaling in aortic smooth muscle cells during thoracic aortic aneurysm formation in Marfan syndrome mice (PMID 41540272). As with the liver and skin work, the reported mechanism was intracellular and cell-type specific rather than systemic.

FGF12 Compared With Secreted FGFs

FGF12 in Research Models: What Studies Report

Because FGF12 has not been studied as an administered compound in the literature cited here, there are no reported adverse-event profiles, tolerability data or human safety findings to summarise. What the published work reports instead are disease-associated consequences of the endogenous protein: a variant linked to early infantile epileptic encephalopathy (PMID 27830185), promotion of liver fibrosis progression when present in macrophages in mice (PMID 35753047), and aberrant mechanosignaling in aortic smooth muscle cells during aneurysm formation in a Marfan syndrome mouse model (PMID 41540272). Several of those findings describe FGF12 activity as contributing to pathology rather than protecting against it, which is an important nuance for anyone reading the name alongside the generally regenerative reputation of the wider FGF family. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or condition.

Limits of the Current Evidence

• Model-bound. The fibrosis and aneurysm findings were reported in mice (PMID 35753047, PMID 41540272), and rodent mechanisms do not automatically translate to humans.
• No administration data. No dose, route, duration or exposure figure for FGF12 appears in the verified literature summarised here, so none is stated.
• Direction depends on tissue. FGF12 was reported to increase keratinocyte proliferation in a psoriasis context (PMID 39234815) while being described as fibrosis-promoting in liver macrophages (PMID 35753047); a single summary sentence cannot describe both.
• Nomenclature confusion. The FHF1 and FGF12 labels refer to the same gene, which the 2016 epilepsy report used interchangeably in its title (PMID 27830185).

Key Takeaways

1. FGF12/FHF1 is an endogenous intracellular protein in the FGF homologous factor subfamily, not a secreted growth factor and not a research injectable, per the 2024 review (PMID 38042708).
2. Human genetics literature associates the gene with early infantile epileptic encephalopathy (PMID 27830185).
3. Mechanistic studies reported roles in keratinocyte proliferation via MDM2/p53 (PMID 39234815), macrophage-driven liver fibrosis in mice (PMID 35753047) and aortic smooth muscle mechanosignaling in mice (PMID 41540272).
4. The term belongs to cell biology and genetics vocabulary; it is definitional here, with no use guidance offered.

References

• FGF12: biology and function (Differentiation; research in biological diversity, 2024)
• FHF1 (FGF12) epileptic encephalopathy (Neurology: Genetics, 2016)
• FGF12 Positively Regulates Keratinocyte Proliferation by Stabilizing MDM2 and Inhibiting p53 Activity in Psoriasis (Advanced Science, 2024)
• Macrophage-specific FGF12 promotes liver fibrosis progression in mice (Hepatology, 2023)
• FGF12 induces aberrant mechanosignaling in aortic smooth muscle cells during thoracic aortic aneurysm formation in Marfan syndrome mice (Experimental & Molecular Medicine, 2026)